Under the law, which was signed by President Barack Obama in December 2016, the payment structure for infusion drugs under Medicare Part B changed from an average wholesale price to an average sales price.
Nearly 80% of respondents reported DIR fees as a very large magnitude challenge, with 83.3% reporting this as a very immediate challenge. Seventy-eight percent of respondents reported MACs not being updated quickly enough to reflect changes in wholesale drug costs as a very large magnitude challenge, with nearly 80% indicating it as a very immediate challenge.
CVS Health president and CEO Larry Merlo was the guest on Boston’s WBUR radio station’s “Here & Now” Tuesday, speaking with host Jeremy Hobson about such topics as tax reform, Amazon’s potential entry into pharmacy and the ongoing question of what changes will come to health care as the Senate considers the American Health Care Act. “I think there are elements that make sense from the Republican plan, but clearly there are other elements the Republican plan does not deal with,” Merlo said. “I think there are many open questions that have yet to be answered” (WBUR)